The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day sev...

http://ift.tt/2f6aQWm